Noam Kirson
Education
Ph.D., economics, Harvard University; B.A., philosophy, political science, and economics, Hebrew University
Summary of Experience
Dr. Kirson is an applied health economist with extensive experience in health economics and outcomes research (HEOR), strategy and market access, and complex litigation matters. He specializes in the application of advanced statistical methods to the analysis of a variety of real-world and clinical data, as well as the development of advanced modeling tools. He has worked closely with many different stakeholders in the health care industry, including biopharmaceutical and device manufacturers, payers, government agencies, leading law firms, and academic experts. Dr. Kirson has managed numerous HEOR and strategy projects, including novel cost-effectiveness analyses, submissions to health technology assessment (HTA) organizations, the design of outcomes-based contracts, the analysis of pharmaceutical pricing, burden-of-illness studies, comparative-effectiveness research, and budget impact assessments. In the regulatory context, he has supported a successful 510(k) pre-market submission to the US Food and Drug Administration (FDA) on behalf of a medical device manufacturer, including the presentation of statistical analyses to an FDA advisory panel. In litigation, Dr. Kirson’s case work has included the evaluation of antitrust matters in the health care sector and the assessment of issues pertaining to the False Claims Act. His work has resulted in numerous conference presentations and peer-reviewed publications in leading journals such as Nature Reviews Drug Discovery, Health Affairs, Alzheimer’s & Dementia, and Diabetes Care, as well as various pharmacoeconomic journals. He has also published in non-academic outlets such as Health Affairs Forefront, STAT, and Law360. Dr. Kirson served on the board of the ISPOR Boston Regional Chapter, including a term as the Chapter President. He is also a member of the editorial board of the journal Pharmacoeconomics Open.
-
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
Pharmacoeconomics, 2024
2024Yee CW, Harvey MJ, Xin Y, Kirson NY
-
Impact of Differential Rates of Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Findings from a Longitudinal Cohort Analysis
The Journal of Prevention of Alzheimers, 2024
2024Chandler J, Georgieva M, Desai U, Done N, Gomez-Lievano A, Ye W, Zhao A, Eid D, Hilts A, Kirson N, Schilling T
-
Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Estimates from Real-World Data
The Journal of Prevention of Alzheimer's Disease, 2024
2024Chandler J, Done N, Desai U, Georgieva M, Gomez-Lievano A, Ye W, Zhao A, Eid D, Hilts A, Kirson N, Schilling T
-
New Vaccine Platforms-Novel Dimensions of Economic and Societal Value and Their Measurement
Vaccines, 2024
2024Buck PO, Gomes DA, Beck E, Kirson N, Mattera M, Carroll S, Ultsch B, Jayasundara K, Uhart M, Garrison LP Jr
-
Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer
European Urology Open Science, 2024
2024Preston MA, Hong A, Dufour R, Marden JR, Kirson NY, Gatoulis SC, Kongara S, Gandhi R, Morgans AK
-
Comprehensive measurement of biopharmaceutical R&D investment
Nature Reviews Drug Discovery, August 2024
2024Chandra A, Drum J, Daly M, Mirsberger H, Spare S, Neumann U, Martin S, Kirson N
-
Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the Nacc Database
Neurology and Therapy, 2023
2023Chandler J, Georgieva M, Desai U, Kirson N, Lane H, Cheung HC, Westermeyer B, Biglan K
-
Health Care Resource Utilization by Patients with Alagille Syndrome
The Journal of Pediatrics, 2023
2023Ebel NH, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P
-
Costs of Pediatric Liver Transplantation among Commercially- and Medicaid-Insured Patients with Cholestasis in the United States
Liver Transplantation, 2023
2023Miloh T, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P
-
Direct health care costs associated with COVID-19 in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022DeMartino J, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N
-
Maralixibat Treatment Response in Alagille Syndrome Is Associated with Improved Health-Related Quality of Life
The Journal of Pediatrics, 2022
2022Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E
-
Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data
Molecular Genetics and Metabolism Reports, 2022
2022Lah M, Cook K, Aparna Gomes D, Liu S, Tabatabaeepour N, Kirson N, Chen E, Lindstrom K, Bulloch Whitehall K, Van Backle J, Burton BK
-
Physician perceptions of drug utilization management: Results of a national survey
PLOS One, 2022
2022Edwards ML, Yin PT, Kuehn M, Bratti K, Kirson N, Jena AB, Howell S
-
The societal economic value of COVID-19 vaccines in the United States
Journal of Medical Economics, 2022
2022Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P
-
Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group
Public Health, 2022
2022Kirson N, Swallow E, Lu J, Foroughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P
-
Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay: A Systematic Review and Meta-Analysis
Antibiotics, 2022
2022Hueth KD, Thompson-Leduc P, Totev TI, Milbers K, Timbrook TT, Kirson N, Hasbun R
-
The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey
PharmacoEconomics, 2022
2022Edwards ML, Yin PT, Kuehn M, Bratti K, Kirson N, Jena A, Howell S
-
The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?"
Diabetic Medicine, 2022
2022Stuckey HL, Desai U, King SB, Popadic L, Levinson W, Kirson NY, Hankosky ER, Mitchell B
-
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes
Journal of Comparative Effectiveness Research, 2022
2022Thach A, Zichlin ML, Kirson N, Yang K, Gaburo K, Pappert E, Mehta D, Williams GR
-
Epidemiology and economic burden of Lewy body dementia in the United States
Current Medical Research and Opinion, 2022
2022Desai U, Chandler J, Kirson N, Georgieva M, Cheung HC, Westermeyer B, Lane H, Biglan K
-
Assessing Barriers to Access and Equity for COVID-19 Vaccination in the US
BMC Public Health, 2022
2022Kuehn M, LaMori J, DeMartino JK, Mesa-Frias M, Doran J, Korrapati L, Bhojwani R, Lefebvre P, Kirson N
-
The Economic Burden of Schizophrenia in the United States
Journal of Clinical Psychiatry, 2022
2022Kadakia A, Catillon M, Fan Q, Williams GR, Marden JR, Anderson A, Kirson N, Dembek C
-
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
Journal of Comparative Effectiveness Research, 2021
2021Desai U, Kirson NY, Guglielmo A, Le HH, Spittle T, Tseng-Tham J, Shawi M, Sheehan JJ
-
Outcomes and resource use of patients with large hemispheric infarction and cerebral edema: analysis of real-world data
Current Medical Research and Opinion, 2021
2021Chen SY, Thompson-Leduc P, Sawyer Jr RN, Fakih I, Cheung HC, Macheca M, Kirson NY, Torbey M
-
Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease
Journal of Health Economics and Outcomes Research, 2021
2021Thach A, Kirson N, Zichlin ML, Dieye I, Pappert E, Williams GR
-
Decreased antibiotic exposure using a procalcitonin protocol for respiratory infections and sepsis in US community hospitals (ProCommunity)
Current Medical Research and Opinion, 2021
2021DeSear KE, Thompson-Leduc P, Van Schooneveld TC, Kirson N, Chritton JJ, Ie S, Cheung HC, Ou S, Zimmer L, Schuetz P
-
Financing Drug Innovation in the US: Current Framework and Emerging Challenges
Pharmacoeconomics, 2020
2020 -
Disease severity at the time of initial cognitive assessment is related to prior health-care resource use burden
Alzheimer's & Dementia, 2020
2020 -
ProCommunity: procalcitonin use in real-world US community hospital settings
Current Medical Research and Opinion, 2020
2020DeSear KE, Thompson-Leduc P, Kirson N, Chritton JJ, Ie S, Van Schooneveld TC, Cheung HC, Ou S, Schuetz P
-
Author’s Contribution: Effect of Delayed Treatment Intensification on Glycemic Control in the Real World
ERICAS Blog, March 19, 2019
2019 -
Temporal and Geographic Variation in the Incidence of Alzheimer’s Disease Diagnosis in the US between 2007 and 2014
Journal of the American Geriatrics Society, December 3, 2019
2019Kirson N, Meadows ES, Desai U, Smith BP, Cheung HC, Zuckerman P, Matthews BR
-
Mild traumatic brain injury in the United States: demographics, brain imaging procedures, health-care utilization and costs
Brain Injury, 2019
2019Pavlov V, Thompson-Leduc P, Zimmer L, Wen J, Shea J, Beyhaghi H, Toback S, Kirson N, Miller M
-
Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker
Journal of Medical Economics, 2019
2019Berdugo MA, Kirson NY, Zimmer L, Beyhaghi H, Toback S, Scarpati LM, Stone MN, Dember R, Tseng-Tham J, Wen J, Miller M
-
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
Alzheimer's & Dementia, 2019
2019Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR
-
Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease
Journal of Alzheimer's Disease. Nov 14 2018;61(1):295-307
2018Kirson NY, Scott Andrews J, Desai U, King SB, Schonfeld S, Birnbaum HG, Ball DE, Kahle-Wrobleski K
-
Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
Clinical Chemistry and Laboratory Medicine. May 1 2018
2018Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, Iankova I, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P
-
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
Health Affairs, June 28, 2018
2018 -
We Need to Improve Medicare’s Annual Wellness Visit to Better Detect Early Dementia
STAT, July 20, 2018
2018Â
-
Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England
BMJ Open. Mar 22 2018;8(3):e019684
2018Dell'Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J
-
The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
Applied Health Economics and Health Policy. 2018 Oct;16(5):609-632
2018Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG
-
Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes
Diabetes Care. 2018 Oct;41(10):2096-2104
2018Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J
-
Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England
BMJ Open. 2018 Mar 22;8(3):e019684
2018Dell'Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J
-
Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2017;6:65-74
2017Andrews JS, Desai U, Kirson NY, Enloe CJ, Ristovska L, King S, Birnbaum HG, Fleisher AS, Ye W, Kahle-Wrobleski K
-
The Economic Burden of Opioid Abuse: Updated Findings
Journal of Managed Care and Specialty Pharmacy. Apr 2017;23(4):427-445
2017Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ
-
Opioid abuse: A detailed examination of cost drivers over a 24-month follow-up period
Journal of Managed Care and Specialty Pharmacy. 01 Nov 2017;23(11):1110-1115
2017Scarpati LM, Kirson NY, Jia ZB, Wen J, Howard J
-
Drivers of excess costs of opioid abuse among a commercially insured population
American Journal of Managed Care. May 2017;23(5):276-282
2017Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC
-
Insurance Switching and Mismatch Between the Costs and Benefits of New Technologies
The American Journal of Managed Care, December 2017
2017Cutler D, Ciarametaro M, Long G, Kirson N, Dubois R
-
Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis
Critical Care Medicine. Dec 21 2017
2017Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P
-
Basal Insulin Persistence, Associated Factors, and Outcomes after Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
Diabetes Therapy. Feb 2017;8(1):149-166
2017Hadjiyianni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M
-
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US
Current Medical Research and Opinion, 2016 04; 32(4): 669-680. e-pub ahead of print 2015/12/26
2016Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.
-
Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population
Journal of Alzheimer's Disease, 2016 05. doi: 10.3233/JAD-150685
2016Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.
-
The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals
Pain Med. 2015 Apr 30. doi: 10.1111/pme.12768
2015Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R
-
Sources of prescription opioids among diagnosed opioid abusers
Curr Med Res Opin. 2015 Apr;31(4):779-84
2015Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R
-
The economic burden of diagnosed opioid abuse among commercially insured individuals
Postgrad Med. 2014 Jul;126(4):53-8
2014Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R
-
Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data
Appl Health Econ Health Policy. 2014 Aug;12(4):435-46
2014Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R
-
Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States
Pain Med. 2014 Sep;15(9):1450-4. doi: 10.1111/pme.12489. Epub 2014 Jul 8
2014Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E
-
Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act
Health Affairs, 2011, 30(11), 2157-2166
2011Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N
-
Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl
J Med Econ. 2011 Oct 28.
2011Kirson N, White A, Birnbaum H, Schiller M, Waldman T, Peterson K, Ben-Joseph R, Berner T, Summers K
-
Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a U.S. privately insured population
Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87.
2011Kirson N, Birnbaum H, Ivanova J, Waldman T, Joish V, Williamson T
-
Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States
Curr Med Res Opin. 2011 Sep;27(9):1763-8.
2011Kirson N, Birnbaum H, Ivanova J, Waldman T, Joish V, Williamson T
-
Excess costs associated with patients with pulmonary arterial hypertension in a U.S. privately insured population
Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303.
2011Kirson N, Birnbaum H, Ivanova J, Waldman T, Joish V, Williamson T
-
Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5 percent
J Med Econ. 2010 Sep;13(3):472-81
2010Kirson N, Ivanova J, Birnbaum H, Kantor E, Amy Puenpatom R, Ben-Joseph R, Summers K
-
Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5 percent versus gabapentin or pregabalin
J Med Econ. 2010 Sep;13(3):482-91
2010Kirson N, Ivanova J, Birnbaum H, Kantor E, Puenpatom R, Ben-Joseph R, Summers K
-
June 8, 2022
-
May 7, 2023
-
August 13, 2024
-
February 26, 2024
-
May 3, 2023
-
March 3, 2023
-
February 13, 2023
-
July 11, 2022
-
April 13, 2021